A Las Vegas resident is the first patient in the world to take part in a new clinical trial to treat his stage four metastatic prostate cancer.
Anthony Brasich was diagnosed nearly 10 years ago with stage four prostate cancer that had spread to his bone. He was given two months to live. Now, almost 10 years later, he’s taking part in a new clinical trial to try to slow the cancer down.
The phase one drug is called ARV110 and it works by blocking receptors preventing cancer cells from taking in testosterone.
According to Anthony’s doctor Nicholas Vogelzang with Comprehensive Cancer Center, the drug was developed out of Yale. He says this is not foolproof and doesn’t take the place of chemotherapy and eventually testosterone will most likely find its way around the block to receptors. But Anthony says after two-and-a-half months on the drug he feels great.
“I’m just hoping for people in the future that they’ll make a big breakthrough here,” said Anthony Brasich, cancer patient. “That things will go great for other people. I think about it that I’m the first one. It brings tears to my eyes that I could do things for other people.”
Since this is just phase one, the plan is for other patients to also take part in the clinical trial of the drug and then hopefully get public approval in the next few years.
Doctors say while it’s being used for prostate cancer, the new drug may be good for breast cancer patients if their type of cancer relies on testosterone to thrive.